Please use this identifier to cite or link to this item: https://doi.org/10.3389/fphar.2018.01125
DC FieldValue
dc.titleN-substituted pyrido-1,4-Oxazin-3-ones induce apoptosis of hepatocellular carcinoma cells by targeting NF-?B signaling pathway
dc.contributor.authorMohan, C.D
dc.contributor.authorBharathkumar, H
dc.contributor.authorDukanya, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India
dc.contributor.authorRangappa, S
dc.contributor.authorShanmugam, M.K
dc.contributor.authorChinnathambi, A
dc.contributor.authorAlharbi, S.A
dc.contributor.authorAlahmadi, T.A
dc.contributor.authorBhattacharjee, A
dc.contributor.authorLobie, P.E
dc.contributor.authorDeivasigamani, A
dc.contributor.authorHui, K.M
dc.contributor.authorSethi, G
dc.contributor.authorBasappa, Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Bangalore, India, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India
dc.contributor.authorRangappa, K.S
dc.contributor.authorKumar, A.P
dc.date.accessioned2020-10-27T10:04:52Z
dc.date.available2020-10-27T10:04:52Z
dc.date.issued2018
dc.identifier.citationMohan, C.D, Bharathkumar, H, Dukanya, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India, Rangappa, S, Shanmugam, M.K, Chinnathambi, A, Alharbi, S.A, Alahmadi, T.A, Bhattacharjee, A, Lobie, P.E, Deivasigamani, A, Hui, K.M, Sethi, G, Basappa, Laboratory of Chemical Biology, Department of Chemistry, Bangalore University, Bangalore, India, Department of Studies in Organic Chemistry, University of Mysore, Mysore, India, Rangappa, K.S, Kumar, A.P (2018). N-substituted pyrido-1,4-Oxazin-3-ones induce apoptosis of hepatocellular carcinoma cells by targeting NF-?B signaling pathway. Frontiers in Pharmacology 9 (NOV) : 1125. ScholarBank@NUS Repository. https://doi.org/10.3389/fphar.2018.01125
dc.identifier.issn16639812
dc.identifier.urihttps://scholarbank.nus.edu.sg/handle/10635/181171
dc.description.abstractHepatocellular carcinoma (HCC) is a fatal disease and ranked fifth in cancer related mortality. Persistent activation of NF-?B is responsible for the oncogenesis, metastasis, tumor evasion, anti-apoptosis, angiogenesis and proliferation in HCC. Therefore, designing of chemically novel, biologically potent small molecules that target NF-?B signaling cascade have gained prominent clinical interest. Herein we synthesized a novel class of 4-(substituted)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one by reacting 2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one with various alkyl halides by using combustion derived bismuth oxide. We evaluated the antiproliferative efficacy of newly synthesized compounds against HCC cells and identified 4-(4-nitrobenzyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one (NPO) as lead anticancer agent. In addition, we investigated the effect of NPO on the DNA binding ability of NF-?B and NF-?B regulated luciferase expression in HCC cells. The results demonstrated that NPO can induce significant growth inhibitory effects in HepG2, HCCLM3 and Huh-7 cells in dose and time-dependent manner. Interestingly, NPO induced significant downregulation in p65 DNA binding ability, p65 phosphorylation and subsequent expression of NF-?B dependent luciferase gene expression in diverse HCC cell lines. Further, in silico docking analysis suggested that NPO can show direct physical interaction with NF-?B. Finally, NPO was found to significantly abrogate tumor growth at a dose of 50 mg/kg in an orthotopic mouse model. Thus, we report the potential anticancer effects of NPO as a novel inhibitor of NF-?B signaling pathway in HCC. Copyright © 2018 Mohan, Bharathkumar, Dukanya, Rangappa, Shanmugam.
dc.rightsAttribution 4.0 International
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.sourceUnpaywall 20201031
dc.subject2 [3 (3 oxo 2h pyrido[3,2 b][1,4]oxazin 4(3h) yl)propyl]isoindoline 1,3 dione
dc.subject4 (2,6 dichlorobenzyl) 2h pyrido[3,2 b][1,4]oxazin 3(4h) one
dc.subject4 (4 isopropylbenzyl) 2h pyrido[3,2 b][1,4]oxazin 3(4h) one
dc.subject4 (4 nitrobenzyl) 2h pyrido [3,2 b][1,4]oxazin 3(4h) one
dc.subject4 (cyclohexylmethyl) 2h pyrido[3,2 b][1,4]oxazin 3(4h) one
dc.subject4 [(3 oxo 2h pyrido[3,2 b][1,4]oxazin 4(3h) yl)methyl]benzonitrile
dc.subject4 [(6,6 dimethyl 4 phenyl 5,6 dihydro 4h 1,2 oxazin 3 yl)methyl] 2h pyrido[3,2 b][1,4]oxazin 3(4h) one
dc.subject4 [4 (tert butyl)benzyl] 2h pyrido[3,2 b][1,4]oxazin 3(4h) one
dc.subject4 [[4 (4 chlorophenyl) 6,6 dimethyl 5,6 dihydro 4h 1,2 oxazin 3 yl]methyl] 2h pyrido[3,2 b][1,4]oxazin 3(4h) one
dc.subject4' [(3 oxo 2h pyrido[3,2 b][1,4]oxazin 4(3H) yl)methyl] [1,10 biphenyl] 2 carbonitrile
dc.subjectantineoplastic agent
dc.subjectDNA
dc.subjectimmunoglobulin enhancer binding protein
dc.subjectliver protective agent
dc.subjectluciferase
dc.subjecttranscription factor RelA
dc.subjectunclassified drug
dc.subjectanimal experiment
dc.subjectanimal model
dc.subjectanimal tissue
dc.subjectantiproliferative activity
dc.subjectapoptosis
dc.subjectArticle
dc.subjectcancer inhibition
dc.subjectcell viability
dc.subjectcomputer model
dc.subjectcontrolled study
dc.subjectdose response
dc.subjectdown regulation
dc.subjectdrug effect
dc.subjectdrug efficacy
dc.subjectdrug identification
dc.subjectdrug potency
dc.subjectdrug synthesis
dc.subjectfemale
dc.subjectgene expression regulation
dc.subjectHCCLM3 cell line
dc.subjectHep-G2 cell line
dc.subjectHuh-7 cell line
dc.subjectIC50
dc.subjectliver cell carcinoma
dc.subjectluciferase gene
dc.subjectmolecularly targeted therapy
dc.subjectmouse
dc.subjectnonhuman
dc.subjectpharmacological parameters
dc.subjectprotein DNA binding
dc.subjectprotein expression
dc.subjectprotein phosphorylation
dc.subjecttime dependence
dc.subjecttumor volume
dc.typeArticle
dc.contributor.departmentPHARMACOLOGY
dc.description.doi10.3389/fphar.2018.01125
dc.description.sourcetitleFrontiers in Pharmacology
dc.description.volume9
dc.description.issueNOV
dc.description.page1125
Appears in Collections:Elements
Staff Publications

Show simple item record
Files in This Item:
File Description SizeFormatAccess SettingsVersion 
10_3389_fphar_2018_01125.pdf4.56 MBAdobe PDF

OPEN

NoneView/Download

Google ScholarTM

Check

Altmetric


This item is licensed under a Creative Commons License Creative Commons